Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Common Equity: 2022-2024

Historic Common Equity for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $502.8 million.

  • Day One Biopharmaceuticals' Common Equity fell 18.83% to $450.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $450.9 million, marking a year-over-year decrease of 18.83%. This contributed to the annual value of $502.8 million for FY2024, which is 45.08% up from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Common Equity is $502.8 million, which was up 45.08% from $346.5 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Common Equity ranged from a high of $502.8 million in FY2024 and a low of $332.0 million during FY2022.
  • Moreover, its 3-year median value for Common Equity was $346.5 million (2023), whereas its average is $393.8 million.
  • Data for Day One Biopharmaceuticals' Common Equity shows a peak YoY skyrocketed of 45.08% (in 2024) over the last 5 years.
  • Over the past 3 years, Day One Biopharmaceuticals' Common Equity (Yearly) stood at $332.0 million in 2022, then grew by 4.37% to $346.5 million in 2023, then surged by 45.08% to $502.8 million in 2024.